Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults

Cressey, Tim R. PhD; Hazra, Rohan MD; Wiznia, Andrew MD; Foca, Marc MD; Jean-Philippe, Patrick MD; Graham, Bobbie BS; King, Jennifer R. PharmD; Britto, Paula PhD; Carey, Vincent J. PhD; Acosta, Edward P. PharmD; Yogev, Ram MDfor the IMPAACT P1058A Team

The Pediatric Infectious Disease Journal: December 2016 - Volume 35 - Issue 12 - p 1333–1335
doi: 10.1097/INF.0000000000001320
HIV Reports

HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.

From the *Program for HIV Prevention and Treatment (IRD UMI 174), Faculty of Associated Medical Sciences, Department of Medical Technology, Chiang Mai University, Chiang Mai, Thailand; Harvard T.H Chan School of Public Health, Boston, Massachusetts; National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Maternal and Pediatric Infectious Disease Branch, Bethesda, Maryland; §Jacobi Medical Center, Bronx, New York; Columbia University Medical Center, New York, New York; HJF-DAIDS, a Division of The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Contractor to NIAID, NIH, DHHS, Bethesda, Maryland; **Frontier Science & Technology, Amherst, New York, New York; ††University of Alabama at Birmingham, Birmingham, Alabama; and ‡‡Children’s Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Accepted for publication March 8, 2016.

J.R.K., PharmD is currently at the Clinical Pharmacokinetics, AbbVie Inc., North Chicago, Illinois.

Supported by National Institutes of Health, US.

The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

The authors have no conflicts of interest to disclose.

Address for correspondence: Tim R. Cressey, PhD, PHPT-IRD UMI 174, Faculty of Associated Medical Sciences, Department of Medical Technology, 6th Floor, 110 Inthawaroros Road, Mueang Chiang Mai 50200, Thailand. E-mail:

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.